title: Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis.
abstract: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of T cells, eosinophils and macrophages in lesional skin. Recently, macrophage-derived chemokine (MDC)/CCL22, a CC chemokine, was identified as a selective chemoattractant for CC chemokine receptor 4 (CCR4)-expressing cells, in addition to thymus and activation-regulated chemokine (TARC). We have previously reported that serum TARC levels correlate with the severity of AD. In this report, we investigated the participation of MDC in AD. First, we measured serum MDC levels in 45 patients with AD, 25 patients with psoriasis vulgaris and 25 healthy controls. Serum MDC levels in AD patients were significantly higher than those in healthy controls and psoriasis patients. Furthermore, the increases in serum MDC levels in AD patients were greater in the severely affected group than in the moderate or mild groups. We compared serum MDC levels in 11 AD patients, before and after treatment, and observed a significant decrease after treatment. Moreover, the serum MDC levels significantly correlated with the Scoring AD (SCORAD) index, serum soluble (s) E-selectin levels, serum soluble interleukin-2 receptor (sIL-2R) levels, serum TARC levels and eosinophil numbers in peripheral blood. Our study strongly suggests that serum MDC levels have a notable correlation with disease activity and that MDC, as well as the CC chemokine TARC, may be involved in the pathogenesis of AD.
authors.affiliation: Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. KAKINUMAT-DER@h-u.tokyo.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Kakinuma
authors.forename: K
authors.initials: K
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Wakugawa
authors.forename: H
authors.initials: H
authors.lastname: Mitsui
authors.forename: Y
authors.initials: Y
authors.lastname: Tada
authors.forename: H
authors.initials: H
authors.lastname: Saeki
authors.forename: H
authors.initials: H
authors.lastname: Torii
authors.forename: M
authors.initials: M
authors.lastname: Komine
authors.forename: A
authors.initials: A
authors.lastname: Asahina
authors.forename: K
authors.initials: K
authors.lastname: Tamaki
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D019742:Chemokines, CC / Q000097:blood*; D003876:Dermatitis, Atopic / Q000097:blood* / Q000188:drug therapy; D019040:E-Selectin / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D011565:Psoriasis / Q000097:blood; D015375:Receptors, Interleukin-2 / Q000097:blood; D012720:Severity of Illness Index; D012995:Solubility
chemical_list: D000305:Adrenal Cortex Hormones; C106230:CCL17 protein, human; C515482:CCL22 protein, human; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D019742:Chemokines, CC; D019040:E-Selectin; D006634:Histamine H1 Antagonists; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2